520
Participants
Start Date
May 5, 2020
Primary Completion Date
March 31, 2021
Study Completion Date
March 31, 2021
Lenzilumab
Administered as an intravenous (IV) infusion
Standard of Care
Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
Mercy Medical Center, Rockville Centre
MedStar Washington Hospital Center, Washington D.C.
Atrium Health, Charlotte
Emory University, Atlanta
Mayo Clinic, Jacksonville
AdventHealth Orlando, Orlando
St. Elizabeth Healthcare, Edgewood
Hennepin County Medical Center, Minneapolis
Mayo Clinic, Rochester
Texas Health, Dallas
St. David's Healthcare, Austin
St. David's North Austin Medical Center, Austin
Mayo Clinic, Phoenix
University of Southern California (USC) Medical Center, Los Angeles
USC - Los Angeles County Medical Center, Los Angeles
University of California, Irvine, Irvine
Dartmouth-Hitchcock, Lebanon
Saint Barnabas Medical Center, Livingston
Hospital Vera Cruz, Belo Horizonte
CPCLIN - Centro de Pesquisas Clínicas de Natal, Natal
Hospital São Lucas - PUCRS, Porto Alegre
Sociedade Literaria e Caritativa Santo Agostinho, Criciúma
Hospital Dia do Pulmão, Blumenau
Hospital Guilherme Alvaro, Santos
CEMEC - Centro Multidisciplinar de Estudos Clínicos LTDA-EPP, São Bernardo do Campo
Clinica de Alergia Martti Antila S/S LTDA, Sorocaba
Escola Paulista de Medicina (UNIFESP), São Paulo
Hospital Heliópolis, São Paulo
Hospital São Luiz do Jabaquara/IDOR, São Paulo
Lead Sponsor
Humanigen, Inc.
INDUSTRY